Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Stem Cell Transcription Factor Sox2 Is Expressed in a Subset of Folliculo-stellate Cells of Growth Hormone-Producing Pituitary Neuroendocrine Tumours and Its Expression Shows No Association with Tumour Size or IGF1 Levels: a Clinicopathological Study of 109 Cases

J. Soukup, T. Česák, H. Hornychová, K. Michalová, Ľ. Michnová, D. Netuka, J. Čáp, F. Gabalec

. 2020 ; 31 (4) : 337-347. [pub] -

Language English Country United States

Document type Journal Article

Grant support
NV19-01-00435 Ministerstvo Zdravotnictví Ceské Republiky

E-resources Online Full text

NLK ProQuest Central from 1997-04-01 to 1 year ago
Medline Complete (EBSCOhost) from 1997-03-01 to 1 year ago
Health & Medicine (ProQuest) from 1997-04-01 to 1 year ago

Sox2 is one of the transcription factors responsible for the maintenance of stem cell phenotype. It has been implicated as a marker of stem cells in normal pituitaries and pituitary neuroendocrine tumours. To explore the clinical significance of Sox2 expression in histological sections, we performed immunohistochemical detection of Sox2 in 113 pituitary neuroendocrine tumours from 109 patients with acromegaly. In 11 tumours, we performed double immunostaining for Sox2, annexin A1 and S100 protein. Tumours were characterised using the WHO classification system. Proliferative activity and invasion were assessed. The amount of immunoreactive cells was evaluated and correlated with tumour size and biochemical features (levels of IGF1, GH, prolactin, βTSH). Sox2+ cells were identified in 35/38 normal pituitaries adjacent to the tumours. In 36 tumours (33%), ≥ 1% of the cells expressed Sox2, in 24 cases (22%), Sox2+ cells comprised < 1% and 49 cases (45%) were negative. We found no significant differences between Sox2+ and Sox2- groups with respect to the age, initial levels of GH, IGF1, prolactin, βTSH, tumour size, invasion, proliferative activity or histological features. We observed a positive correlation between Sox2+ cell count and βTSH immunoreactive cells (r = 0.459, p < 0.001) that was further verified by multivariate analysis. Using double stain, the majority of Sox2+ cells coexpressed annexin A1 (average 89%) and S100 protein (average 76.2%) and showed morphological features of folliculo-stellate cells. Sox2+ cells are thus commonly present in growth hormone-producing tumours and normal pituitaries, and their amount does not have any prognostic significance. Most of these cells represent a subpopulation of folliculo-stellate cells, pointing out to their role as a possible stem cell population.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026370
003      
CZ-PrNML
005      
20211026132945.0
007      
ta
008      
211013s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12022-020-09634-1 $2 doi
035    __
$a (PubMed)32632839
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Soukup, Jiri $u The Fingerland Department of Pathology, University Hospital and Faculty of Medicine Hradec Kralove, Charles University, Sokolska 581, 500 05, Hradec Kralove, Czech Republic. 2jiri.soukup@gmail.com
245    10
$a Stem Cell Transcription Factor Sox2 Is Expressed in a Subset of Folliculo-stellate Cells of Growth Hormone-Producing Pituitary Neuroendocrine Tumours and Its Expression Shows No Association with Tumour Size or IGF1 Levels: a Clinicopathological Study of 109 Cases / $c J. Soukup, T. Česák, H. Hornychová, K. Michalová, Ľ. Michnová, D. Netuka, J. Čáp, F. Gabalec
520    9_
$a Sox2 is one of the transcription factors responsible for the maintenance of stem cell phenotype. It has been implicated as a marker of stem cells in normal pituitaries and pituitary neuroendocrine tumours. To explore the clinical significance of Sox2 expression in histological sections, we performed immunohistochemical detection of Sox2 in 113 pituitary neuroendocrine tumours from 109 patients with acromegaly. In 11 tumours, we performed double immunostaining for Sox2, annexin A1 and S100 protein. Tumours were characterised using the WHO classification system. Proliferative activity and invasion were assessed. The amount of immunoreactive cells was evaluated and correlated with tumour size and biochemical features (levels of IGF1, GH, prolactin, βTSH). Sox2+ cells were identified in 35/38 normal pituitaries adjacent to the tumours. In 36 tumours (33%), ≥ 1% of the cells expressed Sox2, in 24 cases (22%), Sox2+ cells comprised < 1% and 49 cases (45%) were negative. We found no significant differences between Sox2+ and Sox2- groups with respect to the age, initial levels of GH, IGF1, prolactin, βTSH, tumour size, invasion, proliferative activity or histological features. We observed a positive correlation between Sox2+ cell count and βTSH immunoreactive cells (r = 0.459, p < 0.001) that was further verified by multivariate analysis. Using double stain, the majority of Sox2+ cells coexpressed annexin A1 (average 89%) and S100 protein (average 76.2%) and showed morphological features of folliculo-stellate cells. Sox2+ cells are thus commonly present in growth hormone-producing tumours and normal pituitaries, and their amount does not have any prognostic significance. Most of these cells represent a subpopulation of folliculo-stellate cells, pointing out to their role as a possible stem cell population.
650    _2
$a akromegalie $x etiologie $x metabolismus $7 D000172
650    _2
$a dospělí $7 D000328
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidský růstový hormon $x metabolismus $7 D019382
650    _2
$a lidé $7 D006801
650    _2
$a insulinu podobný růstový faktor I $x metabolismus $7 D007334
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neuroendokrinní nádory $x komplikace $x patologie $7 D018358
650    _2
$a nádory hypofýzy $x komplikace $x patologie $7 D010911
650    _2
$a transkripční faktory SOXB1 $x metabolismus $7 D055748
650    _2
$a kmenové buňky $x metabolismus $7 D013234
655    _2
$a časopisecké články $7 D016428
700    1_
$a Česák, Tomáš $u Department of Neurosurgery, University Hospital and Faculty of Medicine Hradec Kralove, Charles University, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
700    1_
$a Hornychová, Helena $u The Fingerland Department of Pathology, University Hospital and Faculty of Medicine Hradec Kralove, Charles University, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
700    1_
$a Michalová, Květoslava $u Department of Pathology, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic $u Bioptical Laboratory, Ltd., Plzen, Czech Republic
700    1_
$a Michnová, Ľudmila $u Department of Pathology, Military University Hospital Prague, Prague, Czech Republic
700    1_
$a Netuka, David $u Department of Neurosurgery and Neurooncology, 1st Medical Faculty, Charles University, Military University Hospital Prague, Prague, Czech Republic
700    1_
$a Čáp, Jan $u 4th Department of Internal Medicine, University Hospital and Faculty of Medicine Hradec Kralove, Charles University, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
700    1_
$a Gabalec, Filip $u 4th Department of Internal Medicine, University Hospital and Faculty of Medicine Hradec Kralove, Charles University, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
773    0_
$w MED00001517 $t Endocrine pathology $x 1559-0097 $g Roč. 31, č. 4 (2020), s. 337-347
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32632839 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132951 $b ABA008
999    __
$a ok $b bmc $g 1715170 $s 1146877
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 31 $c 4 $d 337-347 $e - $i 1559-0097 $m Endocrine pathology $n Endocr Pathol $x MED00001517
GRA    __
$a NV19-01-00435 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...